Caris Life Sciences: Stronger Fundamentals, Same Conclusion [Seeking Alpha]
Caris Life Sciences (NASDAQ:CAI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $28.00 to $30.00. They now have a "hold" rating on the stock.
The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute
Caris Life Sciences (NASDAQ:CAI) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need [Yahoo! Finance]